Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF SEC filings (Ticker: IMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bitwise MARA Option Income Strategy ETF's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bitwise MARA Option Income Strategy ETF's regulatory disclosures and financial reporting.
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, reported selling 12,500 shares of common stock on June 20, 2025, at a weighted average price of $21.3966 per share (ranging from $21.1228 to $22.0249), resulting in an approximate transaction value of $267,458.
Key details of the transaction:
- The sale was executed according to a Rule 10b5-1 trading plan established on November 15, 2024
- Following the transaction, Lyssikatos maintains indirect beneficial ownership of 965,188 shares through The Lyssikatos Revocable Trust 12/15/2011, where he serves as trustee
- The transaction was reported via Form 4 filing on June 24, 2025
FAQ
What is the current stock price of Bitwise MARA Option Income Strategy ETF (IMRA)?
